Alain Bankier, Interim CEO for Intiva, put out an informative Letter to Shareholders today. He listed Intiva’s management team with a brief background for each. The letter when on to list Intiva’s drug development activities before going into Intiva’s introduction of two new consultants to Intiva’s management team.
The two new consultants are:
Dr. Linda Klumpers has joined our drug development team as a consultant. Dr. Klumpers has a Ph.D. in Clinical Pharmacology from the Leiden University Medical Center in the Netherlands and Professor Schoser of the Frederich-Baur Institut at the University of Munich has also joined our drug development team as a consultant. Dr. Schoser is a Myotonic Dystrophy specialist, which is one of the medical conditions for which we are developing a cannabinoid-based pharmaceutical.
Intiva goes on to explain:
Our innovative research and development strategy, consisting of bringing together an endo-cannabinoid scientist, Dr. Klumpers, with an indication specialist such as Professor Schoser, we believe will prove to be very beneficial. These seasoned and leading specialists are sharing their very specific and in-depth knowledge to benefit Intiva by potentially developing new ways of treating medical disorders with cannabinoid-based medications.
With the recent news regarding Syria using nerve agents against its own population, the use of nerve agents, including sarin gas, is once-again a front-page story. Intiva has licensed intellectual property regarding the use of cannabinoid-based drugs for alleviating some of the symptoms resulting from the exposure to organophosphates, including insecticides and nerve agents. Intiva intends to proceed in the development of cannabinoid and terpene-based formulations, with the objective of filing one or more New Drug Applications (NDAs) with the FDA, probably under special "animal only" protocols for national defense and first responders, since nerve agents cannot be tested on humans. Our pre-clinical drug development activities for the nerve agent product are proceeding. Our formulation lab is currently developing test batches, consisting of synthetic THC and other cannabinoids, so that pre-clinical work can be initiated.
Intiva also gives information regarding XactDose:
Intiva has also licensed a patent and intellectual property for the exact dosing of pill-based cannabinoid medicine. We have branded this product as XactDose. Our business plan for XactDose is to license the technology to the medical cannabis industry globally.
Alain Bankier ends the Intiva letter by acknowledging us, their loyal investors in Intiva:
On behalf of your management team and directors, we thank you for your trust and support. We will keep you apprised as Intiva BioPharma proceeds in implementing its business plans.
I, for one, look forward to new information as it becomes available. Thanks Intiva Management Team.
News 
Market Data 
Discover 
